Companies › TriGemX Bio
1 active drug program in 3 registered trials: 3 Phase 3; Neurology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Elismetrep (K-304) Transient receptor potential cation channel subfamily M member 8 inhibitor | TRPM8 | Phase 3 | Migraine; Acute Migraine | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07645924 | Elismetrep (K-304) | Phase 3 | Migraine | Neurology | Feb 2027 |
| NCT07816367 | Elismetrep (K-304) | Phase 3 | Migraine | Neurology | Oct 2027 |
| NCT07674654 | Elismetrep (K-304) | Phase 3 | Acute Migraine | Neurology | Jun 2028 |
–
Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals Zogenix ML Bio Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.